Rethinking herpes simplex virus: the way to oncolytic agents.
about
Viro-immune therapy: A new strategy for treatment of pancreatic cancerOncolytic viral therapy for pancreatic cancer: current research and future directionsA herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunityPresage of oncolytic virotherapy for oral cancer with herpes simplex virus.Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based VectorsSystemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Oncolytic viruses: From bench to bedside with a focus on safety.Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization.Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cellsThe Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its ReceptorsReplication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaSystemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugsHSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyTumour-specific triple-regulated oncolytic herpes virus to target glioma.Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1Retargeting of viruses to generate oncolytic agents.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Advance in herpes simplex viruses for cancer therapy.Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses.Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics.Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors.Lack of association between human herpesvirus and vestibular schwannoma: analysis of 121 cases.Role of autophagy in oncolytic herpes simplex virus type 1-induced cell death in squamous cell carcinoma cells.Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.Spotlight on… Gabriella Campadelli-Fiume.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumorsHSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
P2860
Q26774641-5EE40A8C-F552-4A74-84CC-0EA2A4EF8459Q27011439-C58FD95B-226B-4416-98E2-1871C6A2E4CEQ27319470-082FB107-E078-4BF6-965C-3C0D0122377EQ33603748-DB2429F7-A67C-4A7D-A251-F1A0E6F5D1B1Q33766379-B8244254-7877-4115-8F6B-6882194C92B6Q34020594-9F172DCB-9CC4-44A2-B24B-9C037EA503B9Q34044071-32618246-ABBE-4C88-9E7C-1A2D0EFC4399Q34237174-4E285D18-59F4-4922-B46E-E15BB571E591Q34574879-C8D4A87B-784A-4834-BF68-A5A266260E9CQ35126723-9ABDB421-99CD-4AA6-8A70-ABC2B62FD846Q35638350-5C4B6C24-8CAB-4761-A294-77FE3F3151D5Q35939421-DC3DBCFF-F855-460D-AD62-60D103C4F47BQ36544212-B59C5650-E06C-4284-B81B-7A4E5E6706DDQ37031896-85BC002C-D08B-444B-A19F-E943FE47BA18Q37104963-AB0272B7-356D-4F48-9CDF-34FD5E00181BQ37317636-51969DDE-717B-4306-A1B7-E97DFD8D488DQ37691560-8A8CB3EF-7693-4906-A61D-472A113603F7Q37982062-CCBD02A1-AA93-472A-9AB4-3506BE34A972Q38008023-27975264-8B2A-4C5F-9B37-6DE99F067D18Q38096940-AE9381E0-948B-4CD8-8602-978955B00DC0Q38523847-260ECC46-62A9-44DE-8E78-10464EE1040CQ38785456-FAFECF23-9DF4-49DF-A2F6-10E9CD599EB5Q38857183-FC262D1B-D702-4E86-81B2-5B1E1F74BC51Q38924543-A35C470E-AC66-43AF-B265-24E9848EBADDQ39025906-7823C4AD-18E8-45D2-8117-D64556829DDEQ39347239-2B0300C8-6EAC-431D-971C-DA68AAE83C16Q41562557-8B8BB431-277A-425C-9527-7542551FA3BDQ41922999-062C5C59-71AD-4624-B6D7-6EDA29378715Q45354666-918E2002-F523-4C4E-AE22-9A92BCD703C6Q47562626-B4CE865A-DC21-47FC-B3A6-DB3FD4EC031AQ54968880-6CC1ADB6-4D52-4801-BF71-9AAE65A6EBD9Q56348401-50479506-DFF9-4AF6-A13E-B505634220AAQ56378150-DEB80954-C3BC-4E31-8312-425B6F359E41
P2860
Rethinking herpes simplex virus: the way to oncolytic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rethinking herpes simplex virus: the way to oncolytic agents.
@en
Rethinking herpes simplex virus: the way to oncolytic agents.
@nl
type
label
Rethinking herpes simplex virus: the way to oncolytic agents.
@en
Rethinking herpes simplex virus: the way to oncolytic agents.
@nl
prefLabel
Rethinking herpes simplex virus: the way to oncolytic agents.
@en
Rethinking herpes simplex virus: the way to oncolytic agents.
@nl
P2093
P2860
P50
P356
P1476
Rethinking herpes simplex virus: the way to oncolytic agents.
@en
P2093
Carla De Giovanni
Laura Menotti
Valentina Gatta
P2860
P304
P356
10.1002/RMV.691
P577
2011-05-27T00:00:00Z